Exchange Transfusion for Severe Babesiosis: Indications and Procedure

What Is Exchange Transfusion and Why It Works
Indications: When to Initiate Exchange Transfusion
The Exchange Transfusion Procedure: Step by Step
Post-Procedure Monitoring and Endpoints
ICU Management of Severe Babesiosis
Why Corticosteroids Are Contraindicated
Evidence Base: Case Series and Case Reports
Special Populations: Asplenic and Immunocompromised Patients
Key Research Papers

What Is Exchange Transfusion and Why It Works for Babesiosis

Exchange transfusion (ET) is a procedure in which a patient's blood is simultaneously removed and replaced with donor packed red blood cells (pRBCs) or whole blood, effectively swapping out a large fraction of the circulating blood volume in a controlled, continuous fashion. Unlike a simple top-up transfusion — which only adds donor blood to what is already circulating — exchange transfusion performs a dual function: it removes harmful elements while restoring healthy red cell mass at the same time. This distinction is critical in severe Babesiosis, where the problem is not just a deficit of red cells but an active accumulation of parasitized cells, toxic breakdown products, and inflammatory mediators that continue to drive organ damage even while antiparasitic drugs are being given.

In Babesiosis, the parasite Babesia microti (and related species such as B. duncani and B. divergens) invades red blood cells and replicates inside them, eventually lysing the host cell and releasing merozoites that infect new cells. At high parasitemia levels — 10% or more of circulating red cells infected — the body faces a cascade of simultaneous assaults: massive intravascular hemolysis releases free hemoglobin that injures kidney tubules; inflammatory cytokines generated in response to parasitemia drive systemic inflammation and capillary leak; metabolic waste products from billions of lysing cells overwhelm hepatic clearance; and the sheer loss of functional red cell mass starves tissues of oxygen. Antiparasitic drugs alone, even highly effective regimens like atovaquone-azithromycin, require hours to days to reduce parasitemia meaningfully. In patients with high-grade parasitemia and already-failing organs, that window of time can be fatal.

Exchange transfusion collapses that dangerous window. A single partial exchange — replacing roughly 50 to 100% of the circulating red cell volume — can reduce parasitemia by 60 to 80% within a matter of hours. The mechanism is straightforward: parasitized red cells are physically removed with the blood that is drawn off, while fresh donor pRBCs that contain no parasites are infused in their place. Simultaneously, the removed blood carries away the free hemoglobin that was destined to clog renal tubules, the cytokine-laden plasma that was promoting capillary leak, and circulating toxins that impair platelet and clotting-factor function. The net effect is a rapid reduction in the parasitic burden, a restoration of functional oxygen-carrying capacity, and a clearing of the toxic milieu — all before the antiparasitic drugs have had time to work on their own.

This strategy has deep precedent. Exchange transfusion was developed and refined over decades for sickle cell disease, where it is used to rapidly reduce the percentage of hemoglobin S-bearing cells during acute vaso-occlusive crises and stroke. It has also been employed in severe falciparum malaria with high parasitemia, providing the conceptual and procedural template for its application in Babesiosis. In malaria, ET reduces the load of parasitized cells and removes rosetting factors that cause cerebral microvascular obstruction. The parallel to severe Babesiosis — high parasitemia, hemolysis, organ involvement — made ET a logical intervention, and decades of case reports and case series have borne out its clinical utility.

Indications: When to Initiate Exchange Transfusion

The decision to initiate exchange transfusion in Babesiosis is based on a constellation of clinical and laboratory findings rather than a single hard threshold. Most expert guidelines and consensus statements cite parasitemia of 10% or greater as the primary trigger for considering ET, but this number should never be read in isolation. A patient with 12% parasitemia who is young, immunocompetent, and maintaining adequate hemoglobin may tolerate antiparasitic therapy without ET, while a patient with 7% parasitemia who is asplenic, functionally immunosuppressed, and developing renal failure may need ET urgently.

The most widely cited indication is parasitemia at or above 10%. At this level, the rate of hemolysis and the speed at which organ injury is accumulating typically outpace the kinetics of antiparasitic drug action. Some experts apply a lower threshold — 5% or higher — for patients who have undergone splenectomy, whether surgical or functional (as in sickle cell disease or splenic irradiation). The reason is physiological: the spleen is the primary filter for parasitized and morphologically abnormal red cells. An intact spleen can remove parasitized cells from the circulation continuously, supplementing antiparasitic therapy. A patient without a spleen has lost this clearance mechanism entirely, making the blood-borne parasite burden climb faster and the disease course more precipitous.

Severe hemolysis is an independent indication, even if parasitemia is not yet at the 10% threshold. When hemoglobin falls below 8 g/dL and is continuing to drop despite initiation of antiparasitic therapy, the bone marrow cannot produce new red cells fast enough to compensate, and simple transfusion merely adds cells that the ongoing hemolysis will destroy. ET removes the parasitized cells causing the hemolysis and replaces them with healthy donor cells, breaking the hemolytic cycle.

Pulmonary involvement — including non-cardiogenic pulmonary edema and acute respiratory distress syndrome (ARDS) — is a serious indicator of systemic severity and warrants urgent consideration of ET. Free hemoglobin and inflammatory mediators increase capillary permeability throughout the lung vasculature; high parasitemia sustains this injury continuously. Patients requiring supplemental oxygen at flows above those manageable with simple nasal cannula, or those progressing to require non-invasive or mechanical ventilation, should be evaluated for ET without delay.

Acute kidney injury is both a consequence and an indicator of severe Babesiosis. Free hemoglobin released during intravascular hemolysis is directly nephrotoxic: it precipitates in acidic urine, obstructs renal tubules, and generates reactive oxygen species that injure tubular epithelial cells. Creatinine rising to twice the patient's baseline, oliguria, or the development of frank hemoglobinuria (dark red-brown urine) are warning signs that renal tubular injury is accumulating. Removing the source of free hemoglobin via ET can slow or halt this injury, potentially preventing progression to dialysis-dependent renal failure.

Neurological involvement — altered mental status, confusion, seizures, or focal neurological deficits — represents cerebral Babesiosis and mandates urgent management including strong consideration of ET. The mechanisms of cerebral involvement are not fully elucidated but likely include microvascular sludging by parasitized cells, cytokine-mediated blood-brain barrier disruption, and hypoxia from severe anemia. Once neurological deterioration is underway, reversing it requires rapid reduction of parasitemia and restoration of oxygen delivery.

When multiple criteria are present simultaneously — for example, parasitemia of 8%, hemoglobin of 7.5 g/dL, oxygen saturation of 92% on 4 liters nasal cannula, and creatinine of 2.8 mg/dL in an asplenic patient — the threshold for initiating ET should be low and the decision expedited. The compounding nature of these criteria means that waiting for any single parameter to cross a hard threshold risks allowing irreversible organ injury to accumulate while a potentially effective intervention is delayed.

The Exchange Transfusion Procedure: Step by Step

Exchange transfusion for Babesiosis is most commonly performed as a partial exchange, replacing approximately one to two blood volumes (roughly 5 to 10 liters in an adult) of the patient's circulating blood with donor packed red blood cells. Full-volume exchange — replacing virtually the entire circulating blood volume — is rarely necessary and carries greater risks of hemodynamic instability, electrolyte derangements, and transfusion reactions. Most centers report achieving adequate parasitemia reduction with a partial exchange using 2 to 4 units of pRBCs per exchange cycle, with repeat exchanges performed if parasitemia does not fall sufficiently.

The first practical step is establishing adequate vascular access. Peripheral intravenous access with large-bore catheters (16-gauge or larger, in two separate sites) is the minimum requirement for a manual exchange. Many patients admitted in severe condition will already have central venous access placed for other reasons — a triple-lumen central venous catheter (CVC), a Hickman catheter, or a peripherally inserted central catheter (PICC) all provide reliable access. For automated apheresis-based exchange, the blood flow rates required (often 50 to 150 mL/minute) may necessitate a large-bore dialysis-style catheter placed in a femoral, internal jugular, or subclavian vein.

There are two main technical approaches: manual exchange and automated apheresis exchange. In the manual technique, nursing staff or physicians alternately withdraw aliquots of the patient's blood (typically 300 to 500 mL at a time) into collection bags or syringes while simultaneously infusing matched volumes of donor pRBCs through a separate line. This process is labor-intensive and requires careful attention to volume balance — the goal is isovolemic exchange, where the volume removed equals the volume replaced at each step to avoid hemodynamic swings. The manual method is available at virtually any hospital with a blood bank and ICU-level nursing staff, making it the more widely accessible option.

Automated apheresis exchange uses a cell separator machine that draws blood from the patient, separates cellular components from plasma, removes the red cell fraction (which contains the parasitized cells), and returns plasma and infused donor pRBCs to the patient in a continuous loop. This approach offers several advantages: the exchange is faster (typically 2 to 3 hours versus 3 to 5 hours for manual), the volume balance is more precisely controlled by the machine, and the removal efficiency is higher per unit of time. However, it requires specialized apheresis equipment and trained personnel, limiting its availability to larger academic medical centers and regional hospitals with apheresis programs.

A critical principle that must be emphasized: antiparasitic drug therapy must be continued throughout and after exchange transfusion. ET is a rescue maneuver — it mechanically reduces the parasite burden and buys time — but it does not cure the infection. Without active antiparasitic therapy, the remaining parasites (ET cannot achieve complete removal) will continue to replicate and parasitemia will rebound. The combination of ET for rapid burden reduction plus atovaquone-azithromycin (or clindamycin-quinine in severe cases) for ongoing parasite killing is the complete treatment strategy. Neither alone is sufficient in patients who meet criteria for ET.

Blood products used for ET should be cytomegalovirus (CMV)-negative and leukoreduced whenever possible, particularly in immunocompromised patients. For asplenic patients or those receiving immunosuppressive therapy, irradiated blood products are used to prevent transfusion-associated graft-versus-host disease (TA-GvHD), a rare but potentially fatal complication in which donor lymphocytes engraft in the immunocompromised host and attack host tissues. Matching for extended red cell antigen profiles (beyond ABO and Rh) is performed in patients with known alloantibodies or in those who may require multiple transfusions.

Post-Procedure Monitoring and Endpoints

The effectiveness of exchange transfusion is confirmed through serial laboratory monitoring beginning within hours of the procedure's completion. The most direct measure of success is the peripheral blood smear parasitemia. A Giemsa-stained thin blood smear, prepared and read by an experienced microscopist, allows direct counting of the percentage of red blood cells containing visible intraerythrocytic parasites. Smears should be repeated every 12 hours after the initial ET to document the trajectory of parasitemia. A falling parasitemia — even if not yet below the target threshold — indicates that the combination of ET and antiparasitic drugs is working.

The target endpoint for parasitemia after ET is generally below 1% before considering the exchange complete. Some clinicians use a threshold of 5% or below as the initial target for stabilization, with continued antiparasitic therapy expected to reduce the remaining burden further over the following 24 to 48 hours. If parasitemia fails to fall — or rebounds after an initial reduction — a repeat exchange transfusion may be necessary. Rebound parasitemia after ET is not uncommon and reflects the ongoing replication of parasites that were not removed by the exchange, underscoring why continuous antiparasitic therapy is non-negotiable.

The complete blood count (CBC) is monitored every 12 to 24 hours during the acute phase. Hemoglobin and hematocrit reflect the combined effect of ongoing hemolysis, the influx of donor red cells from ET, and the gradually slowing hemolysis as antiparasitic drugs reduce the parasitemia. Platelet counts are often low in severe Babesiosis due to splenic sequestration, consumption in a disseminated intravascular coagulation (DIC)-like state, and immune-mediated destruction. Falling platelet counts below 20,000 per microliter, or any evidence of active bleeding, warrant evaluation for platelet transfusion and coagulopathy management.

The basic metabolic panel (BMP) — including creatinine, blood urea nitrogen, electrolytes, and glucose — is checked every 6 to 12 hours in severe cases. Creatinine trajectory is the key renal metric: if creatinine continues rising despite ET and adequate hydration, the patient may be progressing toward dialysis-dependent renal failure despite the intervention. Electrolyte abnormalities are common after ET, particularly hypocalcemia from citrate toxicity (citrate is used as an anticoagulant in blood products and chelates ionized calcium), and hypokalemia from volume shifts and dilution. Both require monitoring and supplementation.

Liver function tests (LFTs) — AST, ALT, alkaline phosphatase, bilirubin, and albumin — document hepatic involvement, which is common in severe Babesiosis. Bilirubin elevation reflects both the hemolysis (unconjugated bilirubin from heme breakdown) and hepatocellular injury (conjugated bilirubin elevation if hepatocytes are damaged by the inflammatory process or hypoperfusion). Persistently rising or very high bilirubin is a marker of severity and prolonged disease course.

For patients in whom PCR testing was used in the initial diagnosis, quantitative PCR can be used to monitor for persistent low-level parasitemia after the acute phase, when smear sensitivity declines. PCR will remain positive longer than smear in successfully treated patients, but the trajectory (falling cycle threshold, meaning lower parasite DNA concentration) confirms treatment response. PCR positivity alone after clinical and smear improvement does not warrant prolonging or intensifying therapy.

ICU Management of Severe Babesiosis

Exchange transfusion addresses the parasitemia directly, but patients severe enough to meet ET criteria almost invariably require intensive care unit (ICU)-level support for the multiple organ systems simultaneously under assault. Understanding the full picture of ICU management helps patients and families understand why recovery is a multi-week process even after parasitemia has been controlled.

Fluid management in severe Babesiosis is a careful balancing act. The intravascular hemolysis that defines severe disease causes loss of red cell oncotic pressure and shifts fluid out of the intravascular space, potentially causing relative hypovolemia and impaired organ perfusion. At the same time, the same capillary leak syndrome that underlies ARDS can cause fluid administered intravenously to rapidly extravasate into the lungs and soft tissues, worsening pulmonary edema. Clinicians typically monitor for clinical signs of adequate perfusion (blood pressure, urine output, lactate) while using a conservative fluid strategy to avoid exacerbating lung injury — often targeting a net-zero or mildly negative fluid balance once hemodynamic stability is achieved.

Respiratory support ranges from supplemental oxygen via nasal cannula or face mask in mild hypoxemia, through high-flow nasal cannula (HFNC) or non-invasive positive pressure ventilation (NIPPV/BiPAP) in moderate ARDS, to endotracheal intubation and mechanical ventilation in severe ARDS. When mechanical ventilation is required, lung-protective ventilation strategies — low tidal volumes (6 mL/kg of ideal body weight), plateau pressure limits below 30 cmH2O, and prone positioning in refractory hypoxemia — are the standard of care based on evidence from ARDS in other etiologies.

Renal replacement therapy (RRT) becomes necessary in patients who develop oliguric or anuric acute kidney injury that does not respond to optimization of volume status and blood pressure. Continuous renal replacement therapy (CRRT) is often preferred over intermittent hemodialysis in hemodynamically unstable patients because it removes fluid and solutes more gradually, avoiding the rapid shifts in blood pressure that intermittent dialysis can cause. CRRT also provides ongoing removal of inflammatory cytokines, a potential added benefit in the context of the cytokine-driven injury of severe Babesiosis.

Coagulopathy management addresses the disseminated intravascular coagulation-like state that can develop in severe Babesiosis. DIC in this context is driven by the massive endothelial activation, cytokine storm, and release of procoagulant material from lysing red cells. Prolonged prothrombin time, elevated D-dimer, low fibrinogen, and falling platelet counts together define the syndrome. Fresh frozen plasma (FFP) is used to replace consumed clotting factors when the INR rises significantly above 1.5 or in the presence of active bleeding. Cryoprecipitate replaces fibrinogen when levels fall below 100 mg/dL. Platelet transfusions are generally reserved for counts below 20,000/microliter or active hemorrhage, as transfused platelets may be rapidly consumed in an ongoing DIC state.

Vasopressors are required in patients who develop septic shock — a state of distributive circulatory failure driven by the massive systemic inflammatory response to high-grade parasitemia. Norepinephrine is the first-line vasopressor agent for septic shock regardless of etiology, and the same recommendation applies in Babesiosis. Vasopressin may be added as a second agent if hemodynamic targets are not achieved with norepinephrine alone. Corticosteroids as a vasopressor-sparing strategy in refractory septic shock carry particular risks in Babesiosis (discussed in the next section) and require careful individualized decision-making.

Extended ICU stays of one to three weeks are not unusual in severe Babesiosis requiring ET. Patients and families should be counseled that the path to recovery involves parallel resolution of the parasitic infection and repair of the organs injured during the acute phase — kidneys must regenerate tubular epithelium, lungs must clear inflammatory fluid and repair alveolar membranes, and the bone marrow must restore red cell mass. Nutritional support — via enteral feeding whenever possible, parenteral nutrition if the gut is unavailable — is initiated early to support this repair process and prevent the muscle wasting that accelerates in critical illness.

Why Corticosteroids Are Contraindicated

Corticosteroids — including prednisone, methylprednisolone, and dexamethasone — are standard therapy for autoimmune hemolytic anemia (AIHA), a condition that can look disturbingly similar to Babesiosis on initial presentation. Both conditions present with rapidly falling hemoglobin, elevated bilirubin, and a clinical picture of hemolysis. This clinical similarity has historically led to misdiagnosis and the inappropriate use of corticosteroids in patients who actually had Babesiosis, with potentially fatal consequences.

The reason corticosteroids are harmful in Babesiosis is rooted in immunology. The immune response that controls Babesia infection depends critically on macrophage activation and T-cell-mediated killing of parasitized red cells and free merozoites. Corticosteroids suppress both of these arms of the immune response: they inhibit macrophage phagocytic activity, reduce the production of pro-inflammatory cytokines needed for parasite clearance, and impair the T-cell responses that provide adaptive immune control of intraerythrocytic parasites. In the setting of active Babesiosis, immunosuppression with corticosteroids can accelerate parasite replication, worsen parasitemia, and convert a potentially survivable illness into a fatal one.

The practical implication is that any patient presenting with hemolytic anemia — particularly one who is asplenic, immunocompromised, or who lives in or has traveled to a Babesia-endemic area (the Northeastern United States, upper Midwest, or parts of Europe) — must have Babesiosis excluded before corticosteroids are started. The key diagnostic test is the peripheral blood smear: the intraerythrocytic ring forms and tetrad ("Maltese cross") configurations of Babesia are distinctive and allow diagnosis at the bedside. The direct antiglobulin test (direct Coombs test) is typically negative in Babesiosis hemolysis, in contrast to AIHA where it is positive — this is an important distinguishing feature, though a negative Coombs test alone is not sufficient to exclude all causes of hemolytic anemia.

In practice, when a patient is already on corticosteroids for another indication (such as an inflammatory bowel disease, organ transplantation, or autoimmune condition) and develops Babesiosis, the steroids should be tapered as rapidly as the underlying condition allows while antiparasitic therapy is initiated and ET is considered if warranted. Some immunosuppressed patients — particularly transplant recipients on calcineurin inhibitors and mycophenolate mofetil — may have severely impaired immune control of Babesia even after antiparasitic drugs reduce parasitemia, leading to prolonged or relapsing infections that require extended treatment courses.

Cases of corticosteroid-induced exacerbation of Babesiosis have been documented in the literature, including patients in whom long-standing low-level Babesiosis was unmasked and amplified when corticosteroids were added for an unrelated indication. This phenomenon — corticosteroid-precipitated clinical Babesiosis in a patient who had been subclinically infected — serves as a reminder that Babesia can persist at low levels in immunocompetent individuals without causing overt illness, only to cause severe disease when the immune response is suppressed.

Evidence Base: Case Series and Case Reports

The evidence base for exchange transfusion in severe Babesiosis is composed entirely of case reports, case series, and retrospective cohort analyses. This is not a reflection of clinical uncertainty about the utility of ET — experienced clinicians with expertise in tick-borne diseases consistently advocate for its use in high-parasitemia, organ-involved cases — but rather of the practical impossibility of conducting a randomized controlled trial for an intervention used in a rare, acutely life-threatening illness where withholding a potentially effective treatment would be ethically untenable.

The accumulated case literature spans several decades and multiple countries. Early reports from the 1970s and 1980s described individual patients with severe Babesiosis who underwent ET and survived, often after other interventions had failed to halt organ deterioration. As awareness of Babesiosis grew — particularly in the Northeastern United States following recognition of B. microti as the predominant species and the expansion of the tick vector Ixodes scapularis into new geographic areas — the volume of case reports increased substantially.

Systematic reviews of case reports consistently find that patients with parasitemia above 10% who underwent ET had more rapid reductions in parasitemia and — in retrospective comparisons with historical controls or concurrently treated patients who did not receive ET — lower mortality rates. The numbers in these analyses are necessarily small, given the rarity of severe Babesiosis cases requiring ET, but the direction of benefit is consistent across series.

The primary debate in the literature is not whether to perform ET in patients with high-grade parasitemia and organ involvement, but rather the optimal technical approach: partial versus full-volume exchange, manual versus automated apheresis, the optimal number of units to exchange in a single session, and the threshold for initiating a repeat exchange. Most published series and expert consensus favor partial exchange as sufficient in the majority of cases, reserving extended or repeated exchanges for patients who fail to achieve adequate parasitemia reduction after an initial procedure.

An important nuance in interpreting outcome data from Babesiosis ET series is the confounding by indication: the patients who received ET were, by definition, those with the most severe disease. The fact that mortality in ET-treated patients is not dramatically worse than in non-ET-treated patients — despite the ET group having higher baseline parasitemia and more organ involvement — is itself indirect evidence of benefit. A sicker group achieving equivalent or better outcomes compared to a less sick group that received only antiparasitic therapy suggests that ET is reversing some of the excess risk conferred by high parasitemia and severe hemolysis.

Special Populations: Asplenic and Immunocompromised Patients

Among all the risk factors that predispose to severe Babesiosis requiring exchange transfusion, asplenia stands in a category of its own. The spleen performs two critical functions in the defense against intraerythrocytic parasites: it filters parasitized red blood cells out of the circulation through its unique architecture of narrow sinusoids that trap deformed and rigid cells, and it serves as a major site of immune activation where macrophages and lymphocytes encounter antigens and mount specific immune responses against the parasite. Without a functioning spleen — whether absent due to surgical splenectomy, atrophied due to splenic infarction in sickle cell disease, or non-functional due to congenital asplenia — the patient loses both of these protective mechanisms simultaneously.

In asplenic individuals, Babesiosis can progress from mild febrile illness to life-threatening high-grade parasitemia and organ failure within 24 to 48 hours, a trajectory that would take days to weeks in an immunocompetent individual with an intact spleen. The speed of this progression means that asplenic patients with Babesiosis must be monitored intensively from the moment of diagnosis, with very low thresholds for initiating ET. Several expert guidelines recommend considering ET at parasitemia levels of 5% or above in asplenic patients, rather than the 10% threshold used for the general population. The reasoning is straightforward: at 5% parasitemia, an asplenic patient may already be on a rapid upward trajectory toward 15 or 20%, and waiting until the 10% threshold is reached may mean intervening at a point when organ injury is more advanced and harder to reverse.

Patients who are immunocompromised by HIV infection (particularly those with CD4 counts below 200 cells/microliter), active malignancy, organ transplantation, or chronic immunosuppressive therapy for autoimmune conditions face a different set of challenges. Their impaired T-cell and macrophage responses mean that even after parasitemia has been reduced by ET and antiparasitic drugs, the residual parasite burden may not be cleared efficiently. These patients are at risk for relapsing Babesiosis — an initial clinical and parasitological response followed by recrudescence of parasitemia weeks or months later, sometimes after antiparasitic therapy has been discontinued. For this reason, immunocompromised patients typically require longer courses of antiparasitic therapy, extended monitoring after apparent resolution, and close follow-up for signs of relapse.

A specific risk in immunocompromised patients receiving blood transfusions — including the large volumes of donor pRBCs involved in ET — is transfusion-associated graft-versus-host disease (TA-GvHD). In TA-GvHD, donor T lymphocytes contained in the transfused blood are not eliminated by the recipient's immune system (as they would be in an immunocompetent recipient) and instead engraft and proliferate, eventually attacking host tissues in a manner analogous to allogeneic graft-versus-host disease after bone marrow transplantation. The clinical syndrome — fever, rash, diarrhea, and pancytopenia developing 1 to 4 weeks after transfusion — is distinct from Babesiosis itself but can be difficult to distinguish in a patient who is already critically ill. Prevention is straightforward: irradiated blood products, in which donor lymphocytes have been inactivated by gamma irradiation, should be used routinely in immunocompromised patients receiving transfusions, including ET for Babesiosis.

Other transfusion risks that apply to all patients undergoing ET include acute transfusion reactions (febrile non-hemolytic reactions, allergic reactions, and the rare but life-threatening acute hemolytic transfusion reaction due to ABO incompatibility), transfusion-related acute lung injury (TRALI) — an immune-mediated non-cardiogenic pulmonary edema that can mimic or worsen the ARDS already present in severe Babesiosis — and transfusion-associated circulatory overload (TACO) due to the large volumes of blood products administered. Careful volume management, the use of leukoreduced blood products to reduce the risk of TRALI, and pre-procedure ABO and crossmatch compatibility testing mitigate these risks but do not eliminate them entirely. These transfusion risks are real but are weighed against the high risk of death or irreversible organ failure from untreated high-grade parasitemia — for patients who meet ET criteria, the risk-benefit calculation consistently favors intervention.

Key Research Papers

Connections

Back to Table of Contents